ArticleACS nanoscience Au2025
Development of an Immunoassay for Highly Pathogenic Avian Influenza (H5N1) across Diverse Sample Matrices.
Article in ACS nanoscience Au, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Streamlined CRISPR-based assays for detection and subtyping of H5 and H7 avian influenza.iScience · 2026Article
- Biosensor Technologies for Avian Influenza Detection: A New Frontier in Rapid Diagnostics for HPAI.Biosensors · 2026Review
- Recent advances in lateral flow devices and point-of-care diagnostics for highly pathogenic avian influenza A viruses.Journal of virology · 2025Review
- The emergence of highly pathogenic avian influenza H5N1 in dairy cattle: implications for public health, animal health, and pandemic preparedness.European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
Avian influenza of the highly pathogenic subtype H5N1 has emerged as a global health concern, becoming endemic in wild birds and increasingly transmitting to poultry, livestock, and humans. This study aimed to develop a robust immunoassay for the rapid detection of the H5N1 highly pathogenic avian influenza virus across various sample matrices, including sera, milk, eggs, and bird samples. The assay targets the hemagglutinin (HA) protein, chosen for its abundance and accessibility on the virus surface. Utilizing gold nanospheres conjugated with α-HA IgG antibodies, the assay generated distinct colorimetric signals for both negative and positive samples. The test initially demonstrated an effective colorimetric response with a limit of detection (LOD) of 0.16 nM in human serum and was further optimized for running in whole milk, exhibiting an LOD of 1.72 nM. The assay exhibited versatility across different serum types and dairy products, although high-viscosity samples like heavy cream presented challenges. Furthermore, the immunoassay successfully detected HA of H5N1 in complex sample matrices such as oral, cloacal, and fecal samples from birds. This rapid and sensitive immunoassay represents a significant advance in HPAI surveillance tools, improving prospects for real-time detection to control outbreaks.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.